Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in chemotherapy-naïve metastatic prostate cancer
NCT02294461Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Metastatic Prostate Cancer (mPC) comparing Enzalutamide, Placebo and Placebo followed by Enzalutamide (3 arms). Primary endpoint: Time to Prostate-specific Antigen Progression. Started Apr 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT02294461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02294461.